Canaccord Genuity on Lifesciences/Biomedical Devices & Services: 2012 American Academy of Dermatology Highlights
Tweet
Share
E-mailGet Alerts ZLTQ Hot Sheet
Price: $56.48 --0%
Rating Summary:
7 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 3 | New: 2
Rating Summary:
7 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 3 | New: 2
Join SI Premium – FREE
Canaccord Genuity on Lifesciences/Biomedical Devices & Services: 2012 American Academy of Dermatology Highlights
Analyst, William J. Plovanic, said, "We recently attended the American Academy of Dermatology (AAD) annual meeting in San Diego and spoke with a number of management teams, sales and clinical reps, and physicians. We came away with a stronger interest in a space that we believe is well positioned with solid procedure volume growth, relatively low regulatory hurdles (which results in ease of new product introductions), and minimal ASP pressures. Due to these solid fundamentals, we believe the aesthetics industry is well positioned for a year of growth in 2012."
"Body sculpting is the hot topic –– we are focusing on fat. Nearly every major player in the aesthetics space was showcasing its current (or future) solution for the non-invasive fat reduction and/or body sculpting market. While we believe the first mover market advantage has come and gone for Zeltiq, we note that the market will likely remain a two- to three-horse race for the next year. That said, the companies with these technologies (Zeltiq (Nasdaq: ZLTQ), Solta Medical (Nasdaq: SLTM), Cutera (Nasdaq: CUTR) and CynoSure (Nasdaq: CYNO)) are poised to deliver solid results. "
Analyst, William J. Plovanic, said, "We recently attended the American Academy of Dermatology (AAD) annual meeting in San Diego and spoke with a number of management teams, sales and clinical reps, and physicians. We came away with a stronger interest in a space that we believe is well positioned with solid procedure volume growth, relatively low regulatory hurdles (which results in ease of new product introductions), and minimal ASP pressures. Due to these solid fundamentals, we believe the aesthetics industry is well positioned for a year of growth in 2012."
"Body sculpting is the hot topic –– we are focusing on fat. Nearly every major player in the aesthetics space was showcasing its current (or future) solution for the non-invasive fat reduction and/or body sculpting market. While we believe the first mover market advantage has come and gone for Zeltiq, we note that the market will likely remain a two- to three-horse race for the next year. That said, the companies with these technologies (Zeltiq (Nasdaq: ZLTQ), Solta Medical (Nasdaq: SLTM), Cutera (Nasdaq: CUTR) and CynoSure (Nasdaq: CYNO)) are poised to deliver solid results. "
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CFRA Upgrades Alstom SA (ALO:FP) (ALSMY) to Hold
- BofA Securities Starts Madrigal Pharmaceuticals (MDGL) at Underperform, 'pivoting to Rezdiffra commercial dynamics'
- UBS Reiterates Neutral Rating on Harley-Davidson (HOG)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
